Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa

Annals of Neurology

Volumn 39, Issue 1, 1996, Pages 29-36

  Shoulson, Ira ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; LEVODOPA; SELEGILINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTIOXIDANTS; ANTIPARKINSON AGENTS; DISABLED PERSONS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; SELEGILINE; TREATMENT OUTCOME; VITAMIN E;

EID: 0030042620     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390106     Document Type: Article

References (26)

1. Parkinson Study Group Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364-1371
2. Parkinson Srudy Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183
3. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989; 46:1052-1060
4. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Stoneham, MA: Butterworth-Heinemann, 1989:285-309
5. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
6. Cox DR, Oakes D. Analysis of survival data. In: Statistics and applied probability, vol 21. London: Chapman and Hall, 1984
7. Armitage P, Berry G. Statistical methods in medical research, 2nd ed. Oxford, England: Blackwell, 1987:205
8. Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995;52:237-245
9. Tatton WG. Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 1993;8(suppl 1):S20-S30
10. Ansari KS, Yu PH, Kruck TPA, Tatton WG. Rescue of axotomized immature rat facial motorneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993;13:4042-4053
11. Ju WYH, Holland DP, Tatton WG. (-)-Deprenyl alters the time course of death of axotomized facial motorneurons and the hypertrophy of neighboring astrocytes in immature rats. Exper Neurol 1994;126:233-246
12. Tatton WG, Seniuk NA. Trophic-like' actions of (-)-deprenyl on neurons and astroglia. In: Racagni G, Brunello N, Langer SZ, eds. Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. Int Acad Biomed Drug Res 1994;7:238-248
13. Tipton KF. What is it that L-deprenyl (selegiline) might do? Clin Pharmacol Ther 1994;56:781-796
14. Tatton WG, Ju WYL, Holland DP, et al (-)Deprenyl reduced PC12 cell apoptosis by inducing new protein synthesis J Neurochem 1994;63:1572-1575
15. Hartley A, Stone JM, Heron C, et al. Complex I inhibi tors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994;63:1987-1990
16. Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798
17. Oakes D and the Parkinson Study Group. Antiparkinson efficacy of deprenyl. Ann Neurol 1993;34:634
18. Ward CD. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DAT ATOP study. J Neurol Neurosurg Psychiatry 1994;57:217-220
19. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681
20. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989, 245:519-522
21. Teravainen H. Selegiline in Parkinson's disease. Acta Neurol Scand 1990;81:333-336
22. Allain H, Cougnard J, Neukirch H-C, FSMT members. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). Acta Neurol Scand Suppl 1991;136: 73-78
23. Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992;42:339-343
24. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45
25. Rinne JO, Roytta M, Paljarvi L, et al. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology 1991;41:859-861
26. Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 1985;64:113-127